Disrupting the Oncogenic Synergism between Nucleolin and Ras Results in Cell Growth Inhibition and Cell Death

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Schokoroy, Sari ^a   Juster, Dolly ^a   Kloog, Yoel ^a   Pinkas Kramarski, Ronit ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

APTAMER; AS 1411; GROA; NUCLEOLIN; RAS PROTEIN; SALIRASIB; UNCLASSIFIED DRUG;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL DEATH; CELL GROWTH; CELL MOTILITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; RAT;

ANIMALS; CARCINOGENESIS; CELL DEATH; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FARNESOL; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MICE; MICE, NUDE; MICROSCOPY, FLUORESCENCE; OLIGODEOXYRIBONUCLEOTIDES; PHOSPHOPROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA-BINDING PROTEINS; SALICYLATES;

EID: 84884584927     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0075269     Document Type: Article

References (42)

1. Vojtek AB, Der CJ, (1998) Increasing complexity of the Ras signaling pathway. J Biol Chem 273: 19925-19928. doi:10.1074/jbc.273.32.19925. PubMed: 9685325.
2. Downward J, (1998) Ras signalling and apoptosis. Curr Opin Genet Dev 8: 49-54. doi:10.1016/S0959-437X(98)80061-0. PubMed: 9529605.
3. Harris AL, Nicholson S, Sainsbury R, Wright C, Farndon J, (1992) Epidermal growth factor receptor and other oncogenes as prognostic markers. Monogr Natl Cancer Inst. pp. pp. 181-187.
4. Reddy EP, Reynolds RK, Santos E, Barbacid M, (1982) A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene. Nature 300: 149-152. doi:10.1038/300149a0. PubMed: 7133135.
5. Tabin CJ, Bradley SM, Bargmann CI, Weinberg RA, Papageorge AG, et al. (1982) Mechanism of activation of a human oncogene. Nature 300: 143-149. doi:10.1038/300143a0. PubMed: 6290897.
6. Vigil D, Cherfils J, Rossman KL, Der CJ, (2010) Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy? Nat Rev Cancer 10: 842-857. doi:10.1038/nrc2960. PubMed: 21102635.
7. Aharonson Z, Gana-Weisz M, Varsano T, Haklai R, Marciano D, et al. (1998) Stringent structural requirements for anti-Ras activity of S-prenyl analogues. Biochim Biophys Acta 1406: 40-50. doi:10.1016/S0925-4439(97)00077-X. PubMed: 9545527.
8. Haklai R, Weisz MG, Elad G, Paz A, Marciano D, et al. (1998) Dislodgment and accelerated degradation of Ras. Biochemistry 37: 1306-1314. doi:10.1021/bi972032d. PubMed: 9477957.
9. Elad G, Paz A, Haklai R, Marciano D, Cox A, et al. (1999) Targeting of K-Ras 4B by S-trans,trans-farnesyl thiosalicylic acid. Biochim Biophys Acta 1452: 228-242. doi:10.1016/S0167-4889(99)00144-5. PubMed: 10590312.
10. Marom M, Haklai R, Ben-Baruch G, Marciano D, Egozi Y, et al. (1995) Selective inhibition of Ras-dependent cell growth by farnesylthiosalisylic acid. J Biol Chem 270: 22263-22270. doi:10.1074/jbc.270.38.22263. PubMed: 7673206.
11. McPherson RA, Conaway MC, Gregory CW, Yue W, Santen RJ, (2004) The novel Ras antagonist, farnesylthiosalicylate, suppresses growth of prostate cancer in vitro. Prostate 58: 325-334. doi:10.1002/pros.10336. PubMed: 14968433.
12. Erlich S, Tal-Or P, Liebling R, Blum R, Karunagaran D, et al. (2006) Ras inhibition results in growth arrest and death of androgen-dependent and androgen-independent prostate cancer cells. Biochem Pharmacol 72: 427-436. doi:10.1016/j.bcp.2006.05.007. PubMed: 16780807.
13. Weisz B, Giehl K, Gana-Weisz M, Egozi Y, Ben-Baruch G, et al. (1999) A new functional Ras antagonist inhibits human pancreatic tumor growth in nude mice. Oncogene 18: 2579-2588. doi:10.1038/sj.onc.1202602. PubMed: 10353601.
14. Halaschek-Wiener J, Wacheck V, Schlagbauer-Wadl H, Wolff K, Kloog Y, et al. (2000) A novel Ras antagonist regulates both oncogenic Ras and the tumor suppressor p53 in colon cancer cells. Mol Med 6: 693-704. PubMed: 11055588.
15. Zundelevich A, Elad-Sfadia G, Haklai R, Kloog Y, (2007) Suppression of lung cancer tumor growth in a nude mouse model by the Ras inhibitor salirasib (farnesylthiosalicylic acid). Mol Cancer Ther 6: 1765-1773. doi:10.1158/1535-7163.MCT-06-0706. PubMed: 17541036.
16. Bates PJ, Kahlon JB, Thomas SD, Trent JO, Miller DM, (1999) Antiproliferative activity of G-rich oligonucleotides correlates with protein binding. J Biol Chem 274: 26369-26377. doi:10.1074/jbc.274.37.26369. PubMed: 10473594.
17. Srivastava M, Pollard HB, (1999) Molecular dissection of nucleolin's role in growth and cell proliferation: new insights. FASEB J 13: 1911-1922. PubMed: 10544174.
18. Storck S, Thiry M, Bouvet P, (2008) Conditional knockout of nucleolin in DT40 cells reveals the functional redundancy of its RNA binding domains. Biol Cell.
19. Ugrinova I, Monier K, Ivaldi C, Thiry M, Storck S, et al. (2007) Inactivation of nucleolin leads to nucleolar disruption, cell cycle arrest and defects in centrosome duplication. BMC Mol Biol 8: 66. doi:10.1186/1471-2199-8-66. PubMed: 17692122.
20. Legrand D, Vigié K, Said EA, Elass E, Masson M, et al. (2004) Surface nucleolin participates in both the binding and endocytosis of lactoferrin in target cells. Eur J Biochem 271: 303-317. doi:10.1046/j.1432-1033.2003.03929.x. PubMed: 14717698.
21. Stepanova V, Lebedeva T, Kuo A, Yarovoi S, Tkachuk S, et al. (2008) Nuclear translocation of urokinase-type plasminogen activator. Blood 112: 100-110. doi:10.1182/blood-2007-07-104455. PubMed: 18337556.
22. Destouches D, El Khoury D, Hamma-Kourbali Y, Krust B, Albanese P, et al. (2008) Suppression of tumor growth and angiogenesis by a specific antagonist of the cell-surface expressed nucleolin. PLOS ONE 3: e2518. doi:10.1371/journal.pone.0002518. PubMed: 18560571.
23. Teng Y, Girvan AC, Casson LK, Pierce WM Jr., Qian M, et al. (2007) AS1411 alters the localization of a complex containing protein arginine methyltransferase 5 and nucleolin. Cancer Res 67: 10491-10500. doi:10.1158/0008-5472.CAN-06-4206. PubMed: 17974993.
24. Xu X, Hamhouyia F, Thomas SD, Burke TJ, Girvan AC, et al. (2001) Inhibition of DNA replication and induction of S phase cell cycle arrest by G-rich oligonucleotides. J Biol Chem 276: 43221-43230. doi:10.1074/jbc.M104446200. PubMed: 11555643.
25. Di Segni A, Farin K, Pinkas-Kramarski R, (2008) Identification of nucleolin as new ErbB receptors- interacting protein. PLOS ONE 3: e2310. doi:10.1371/journal.pone.0002310. PubMed: 18523588.
26. Farin K, Di Segni A, Mor A, Pinkas-Kramarski R, (2009) Structure-function analysis of nucleolin and ErbB receptors interactions. PLOS ONE 4: e6128. doi:10.1371/journal.pone.0006128. PubMed: 19578540.
27. Farin K, Schokoroy S, Haklai R, Cohen-Or I, Elad-Sfadia G, et al. (2011) Oncogenic synergism between ErbB1, nucleolin, and mutant Ras. Cancer Res 71: 2140-2151. doi:10.1158/1538-7445.AM2011-2140. PubMed: 21257709.
28. Bates PJ, Laber DA, Miller DM, Thomas SD, Trent JO, (2009) Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Exp Mol Pathol 86: 151-164. doi:10.1016/j.yexmp.2009.01.004. PubMed: 19454272.
29. Cox AD, Der CJ, (2002) Ras family signaling: therapeutic targeting. Cancer Biol Ther 1: 599-606. PubMed: 12642680.
30. Rotblat B, Ehrlich M, Haklai R, Kloog Y, (2008) The Ras inhibitor farnesylthiosalicylic acid (Salirasib) disrupts the spatiotemporal localization of active Ras: a potential treatment for cancer. Methods Enzymol 439: 467-489. doi:10.1016/S0076-6879(07)00432-6. PubMed: 18374183.
31. Kloog Y, Cox AD, (2000) RAS inhibitors: potential for cancer therapeutics. Mol Med Today 6: 398-402. doi:10.1016/S1357-4310(00)01789-5. PubMed: 11006529.
32. Ireson CR, Kelland LR, (2006) Discovery and development of anticancer aptamers. Mol Cancer Ther 5: 2957-2962. doi:10.1158/1535-7163.MCT-06-0172. PubMed: 17172400.
33. Dapic V, [!(surname)!], Trent JO, Rodger A, Thomas SD, Miller DM, (2002) Antiproliferative activity of G-quartet-forming oligonucleotides with backbone and sugar modifications. 2002. Biochemistry 41: 367-385. doi:10.1021/bi011335b. PubMed: 11772036.
34. Reyes-Reyes EM, Teng Y, Bates PJ, (2010) A new paradigm for aptamer therapeutic AS1411 action: uptake by macropinocytosis and its stimulation by a nucleolin-dependent mechanism. Cancer Res 70: 8617-8629. doi:10.1158/0008-5472.CAN-10-0920. PubMed: 20861190.
35. Etienne-Manneville S, (2006) In vitro assay of primary astrocyte migration as a tool to study Rho GTPase function in cell polarization. Methods Enzymol 406: 565-578. doi:10.1016/S0076-6879(06)06044-7. PubMed: 16472688.
36. Goldberg L, Kloog Y, (2006) A Ras inhibitor tilts the balance between Rac and Rho and blocks phosphatidylinositol 3-kinase-dependent glioblastoma cell migration. Cancer Res 66: 11709-11717. doi:10.1158/0008-5472.CAN-06-1878. PubMed: 17178866.
37. Normanno N, Tejpar S, Morgillo F, De Luca A, Van Cutsem E, et al. (2009) Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat Rev Clin Oncol 6: 519-527. doi:10.1038/nrclinonc.2009.111. PubMed: 19636327.
38. Charette N, De Saeger C, Lannoy V, Horsmans Y, Leclercq I, et al. (2010) Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition. Mol Cancer 9: 256. doi:10.1186/1476-4598-9-256. PubMed: 20860815.
39. Takaoka A, Hinoda Y, Satoh S, Adachi Y, Itoh F, et al. (1998) Suppression of invasive properties of colon cancer cells by a metastasis suppressor KAI1 gene. Oncogene 16: 1443-1453. doi:10.1038/sj.onc.1201648. PubMed: 9525743.
40. Yamazaki D, Kurisu S, Takenawa T, (2005) Regulation of cancer cell motility through actin reorganization. Cancer Sci 96: 379-386. doi:10.1111/j.1349-7006.2005.00062.x. PubMed: 16053508.
41. Ridley AJ, Schwartz MA, Burridge K, Firtel RA, Ginsberg MH, et al. (2003) Cell migration: integrating signals from front to back. Science 302: 1704-1709. doi:10.1126/science.1092053. PubMed: 14657486.
42. Di Segni A, Ben-Baruch N, Pinkas-Kramarski R, (2009) The ErbB family of receptor tyrosine kinases:key regulators in breast cancer and other malignancies. In: Ben-Baruch A, eds. Breast cancer: From Pathogenesis to Potential therapeutic Modalities. Kerala: Transworld Research Network. pp. pp. 77-105.